Chemotherapy for malignant pleural mesothelioma: Past results and recent developments

British Journal of Cancer

Volumn 88, Issue 2, 2003, Pages 167-174

  Tomek, S ^a,d   Emri, S ^b   Krejcy, K ^c   Manegold, C ^e  

^a Division of Oncology   (Austria)

^b HACETTEPE UNIVERSITY   (Turkey)

^c Eli Lilly Regional GmbH   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e NONE

Author keywords

Chemotherapy; Malignant pleural mesothelioma

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTIMETABOLITE; CISPLATIN; CYTOTOXIC AGENT; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; TOPOTECAN; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; HUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 0037468116     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600673     Document Type: Review

References (89)

1. Aisner J, Wiernik PH (1981) Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8: 335-343
2. Alberts AS, Falkson G, Van Zyl L (1988) Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 80: 698-700
3. Andersen MK, Krarup-Hansen A, Martensson G, Winther-Nielsen H, Thylen A, Damgaard K, Olling S, Wallin J (1999) Ifosfamide in malignant mesothelioma: a phase II study. Lung Cancer 24: 39-43
4. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP (1980) Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68: 356-362
5. Antman KH, Corson JM. (1985) Benign and malignant pleural mesothelioma. Clin Chest Med 6: 127-140
6. Ardizzoni A, Rosso R, Salvati F, Fusco V, Cinquegrana A, De Palma M, Serrano J, Pennucci MC, Soresi E, Crippa M et al (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67: 2984-2987
7. Aversa SL, Crcuri C, DePangher V et al (1998) Carboplatin and Gemcitabine chemotherapy for malignant pleural mesothelioma (MPM): A phase II study of the GSTPV. Ann of Oncol 9: 117
8. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G (2000) Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 11: 697-700
9. Bajorin D, Kelsen D, Mintzer DM (1987) Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 71: 857-858
10. Bednar ME, Chahinian P (1999) Paclitaxel and carboplatin for malignant mesothelioma. Ann Meet Am Soc Clin Oncol A1916 18: 496a
11. Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH (1999) Docetaxel for malignant mesothelioma: phase II study of the eastern Cooperative Oncology Group (ECOG 2595). Proc Am Soc Clin Oncol 1999 A1829, Vol 18, p.p. 474a
12. Bischoff HG, Manegold C, Knopp M, Blatter J, Drings P (1998) Gemcitabine (Gemzar®) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Ann Meet Am Soc Clin Oncol 17; A1784
13. Bissett D, Macbeth FR, Cram I (1991) The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol) 3: 315-317
14. Boutin C, Irisson M, Guerin JC, Roegel E, Paramelle B, Brambilla C, Jeannin L, Dabouis G, Le Caer H, Viallat JR (1987) Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 71: 205-206
15. Boutin C, Schlesser M, Frenay C, Astoul P (1998) Malignant pleural mesothelioma. Eur Respir J 12: 972-981
16. Breau JL, Boaziz C, Morere JJF (1991) Cobination therapy with cisplatinum, adramycin, bleomycin and mitomycin C plus systemic and intra-pleural hyaluronidase in 25 consecitive cases of stages II, III pleural mesothelioma. Presented at the first International Mesothelioma Conference, Paris, France
17. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17: 25-30
18. Carmichael J, Cantwell BM, Harris AL (1989) A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 25: 911-912
19. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, Herndon II JE, Aisner J, Ellison RR, Leone L et al (1993) Randomised phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11: 1559-1565
20. Colbert N, Vannetzel JM, Izrael V, Schlienger M, Milleron B, Blanchon F, Herman D, Akoun G, Roland J, Chatelet F et al (1985) A prospective study of detorubicin in malignant mesothelioma. Cancer 56: 2170-2174
21. Cowan JD, Green S, Lucas J, Weick JK, Balcerzak SP, Rivkin SE, Coltman CA, Baker LH (1988) Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 6: 247-248
22. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16: 145-152
23. Dimitrov NV, Egner J, Balcueva E, Suhrland LG (1982) High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 50: 1245-1247
24. Dirix LY, van Meerbeeck J, Schrijvers D, Corthouts B, Prove A, van Marck E, Vermeire P, van Oosterom AT (1994) A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 5: 653-655
25. Eisenhauer EA, Evans WK, Murray N, Kocha W, Wierzbicki R, Wilson K (1988) A phase II study of VP-16 and cisplatin in patients with unresectable maignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 6: 327-329
26. Eisenhauer EA, Evans WK, Raghavan D, Desmeules MJ, Murray NR, Stuart-Harris R, Wilson KS (1986) Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep 70: 1029-1030
27. Falkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ (1992) An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 10: 337-343
28. Fizazi K, Caliandro R, Soulie P, Fandi A, Daniel C, Bedin A, Doubre H, Viala J, Rodier J, Trandafir L, Le Chevalier T, Cvitkovic E, Armand J, Ruffie P (2000) Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer 36: 1514-1521
29. Giaccone G, O'Brien M, Byrne MJ, Van Steenkiste J, Cosaert J (2001) Phase II Trial of ZD0473 in Patients with Mesothelioma Relapsing After One Prior Chemotherapy Regimen. Proc Ann. Meet Am Soc Clin Oncol A2781 20: 257b
30. Gridelli C, Pepe R, Airoma G, Incoronato P, Rossi A, Palazzolo G, Bianco AR (1992) Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Tumori 78: 380-382
31. Harvey VJ, Slevin ML, Ponder BA, Blackshaw AJ, Wrigley PF (1984) Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 54: 961-964
32. Henss H, Fiebig HH, Schildge J, Arnold H, Hasse J (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11: 118-120
33. Hilaris BS, Nori D, Kwong E, Kutcher GJ, Martini N (1984) Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 10: 325-331
34. Hughes A, Calvert P, Azzabi A, Plummer A, Johnsons R, Rusthoven R, Griffin M, Fishwick K, Boddy AV, Verril M, Calvert H (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncology 20: 3533-3544
35. Icli F, Karaoguz H, Hasturk S, Kurt B, Akbulut H, Dincol D, Demirkazik A, Cay F, Akyar S (1996) Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer 15: 207-213
36. Kaukel E, Koschel G, Gatzemeyer U, Salewski E (1990) A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 66: 651-654
37. Kelsen D, Gralla R, Cheng E, Martini N (1983) Vindesine in the treatment of malignant mesothelioma: a phase II study. Cancer Treat Rep 67: 821-822
38. Kindler HL, Belani CP, Herndon II JE, Vogelzang NJ, Suzuki Y, Green MR (1999) Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 86: 1985-1991
39. Kindler HL, Herndon JE, Vogelzang NJ, Green MR. (2000). CPT-11 in Malignant Mesothelioma: A Phase II Trial by the Cancer and Leukemia Group B (CALGB 9733). Proc Ann. Meet Am Soc Clin Oncol 27: A1978. Vol. 19, pp. 505a
40. Kindler HL, Millard F, Herndon II JE, Vogelzang NJ, Suzuki Y, Green MR (2001) Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31: 311-317
41. Knuuttila A, Ollikainen T, Halme M, Mali P, Kivisaari L, Linnainmaa K, Jekunen A, Mattson K (2000) Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma-a feasibility study. Anticancer Drugs 11: 257-261
42. Krarup-Hansen A (1996) Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma. Lung Cancer 16: 101-102
43. Kutcher GJ, Kestler C, Greenblatt D, Brenner H, Hilaris BS, Nori D (1987) Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Phys 13: 1747-1752
44. Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB (1996) Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomised phase II study. Eur Respir J 9: 2565-2572
45. Magri MD, Foladore S, Veronesi A, Serra C, Nicotra M, Tommasi M, Grandi G, Monfardini S, Bianchi C (1992) Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol 3: 237-238
46. Magri MD, Veronesi A, Foladore S, De Giovanni D, Serra C, Crismancich F, Tuveri G, Nicotra M, Tommasi M, Morassut S et al (1991) Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)-Mesothelioma Committee. Tumori 77: 49-51
47. Maksymiuk AW, Marschke Jr RF, Tazelaar HD, Grill J, Nair S, Marks RS, Brooks BJ, Mailliard JA, Burton GM, Jett JR (1998) Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 21: 610-613
48. Martensson G, Sorenson S (1989) A phase II study of vincristine in malignant mesothelioma-a negative report. Cancer Chemother Pharmacol 24: 133-134
49. Mattson K, Giaccone G, Kirkpatrick A, Evrard D, Tammilehto L, van Breukelen FJ, Planteydt HT, van Zandwijk N (1992) Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10: 824-828
50. Mbidde EK, Harland SJ, Calvert AH, Smith IE (1986) Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18: 284-285
51. Middleton GW, Smith IE, O'Brien ME, Norton A, Hickish T, Priest K, Spencer L, Ashley S. (1998) Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9: 269-273
52. Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M, Ninomiya K, Yamamoto T, Higashino K (1999) Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 85: 2375-2384
53. Novak A, Byrne M, Williamson R (2002) Multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87: 491-496
54. Oh Y, Perez-Soler R, Fossella FV, Glisson BS, Kurie J, Walsh GL, Truong M, Shin DM (2000) Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 18: 243-245
55. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR (1998) Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 115: 310-317 discussion 317-318
56. Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, Giorgi G, Vigani A, Frola C, Rosso R (1997) Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer 79: 1897-1902
57. Pinto C, Marino A, Guaraldi M, Melotti B, Piana E, Martoni A, Pannuti F (2001) Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 24(2): 143-147
58. Planting AS, van der Burg ME, Goey SH, Schellens JH, van den Bent MJ, de Boer-Dennert M, Stoter G, Verweij J (1995) Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 6: 613-615
59. Raghavan D, Gianoutsos P, Bishop J, Lee J, Young I, Corte P, Bye P, McCaughan B (1990) Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8: 151-154
60. Rusch VW, Venkatraman E (1996) The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111: 815-825 discussion 825-826
61. Sahmoud T, Postmus PE, van Pottelsberghe C, Mattson K, Tammilehto L, Splinter TA, Planting AS, Sutedja T, van Pawel J, van Zandwijk N, Baas P, Roozendaal KJ, Schrijver M, Kirkpatrick A, Van Glabbeke M, Ardizzoni A, Giaccone G (1997) Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 33: 2211-2215
62. Samson MK, Wasser LP, Borden EC, Wanebo HJ, Creech RH, Phillips M, Baker LH (1987) Randomised comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 5: 86-91
63. Samuels BL, Herndon II JE, Harmon DC, Carey R, Aisner J, Corson JM, Suzuki Y, Green MR, Vogelzang NJ (1998) Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 82: 1578-1584
64. Scagliotti G, Shin D, Kindler H, Johnson D, Keppler U (2001) Phase II Study of ALIMTA (pemetrexed disodium, MTA) Single Agent in Patients with Malignant Pleural Mesothelioma. Eur J Cancer 37 (Suppl. 6): 20
65. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK (1995) Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76: 2230-2236
66. Solheim OP, Saeter G, Finnanger AM, Stenwig AE (1992) High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65: 956-960
67. Sorensen PG, Bach F, Bork E, Hansen HH (1985) Randomised trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69: 1431-1432
68. Soubra M, Dunscombe PB, Hodson DI, Wong G (1990) Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 18: 1521-1527
69. Sridhar KS, Hussein AM, Feun LG, Zubrod CG (1989) Activity of pirarubicin (4′-0-tetrahydropyranyladriamycin) in malignant mesothelioma. Cancer, 63: 1084-1091
70. Steele JP, O'Doherty CA, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM (2001) Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 12: 497-499
71. Steele JP, Rudd RM (2000) Malignant mesothelioma: predictors of prognosis and clinical trials. Thorax 55: 725-726
72. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18: 3912-3917
73. Tammilehto L, Maasilta P, Mantyla M, Salo J, Mattson K (1994) Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann Oncol 5: 949-950
74. Thodtmann R, Depenbrock H, Blatter J, Johnson RD, van Oosterom A, Hanauske AR (1999) Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors. Semin Oncol 26: 89-93
75. Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E, Skarlos D, Pavlidis N, Stamatelos G, Kosmidis P (1994) Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 11: 299-303
76. van Breukelen FJ, Mattson K, Giaccone G, van Zandwijk N, Planteydt HT, Kirkpatrick A, Dalesio O (1991) Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 27: 1627-1629
77. Van Haarst JW, Burgers JA, Manegold CH et al (2000) Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM). Program and abstracts of the 9th World Conference on Lung Cancer; September 11-15, Tokyo, Japan. Abstract 56
78. van Meerbeeck JP, Baas P, Debruyne C, Groen HJ, Manegold C, Ardizzoni A, Gridelli C, van Marck EA, Lentz M, Giaccone G (1999) A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 85: 2577-2582
79. van Meerbeeck J, Debruyne C, van Zandwijk N, Postmus PE, Pennucci MC, van Breukelen F, Galdermans D, Groen H, Pinson P, van Glabbeke M, van Marck E, Giaccone G (1996) Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 74: 961-963
80. Verschraegen C, Le D, Kudelka A, Kavanagh J, Hunt K (2001) Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma. Proc Ann Meet Am Soc Clin Oncol A2110 20: 90
81. Vogelzang NJ, Goutsou M, Corson JM, Suzuki Y, Graziano S, Aisner J, Cooper MR, Coughlin KM, Green MR (1990) Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27: 239-242
82. Vogelzang NJ, Herndon II JE, Cirrincione C, Harmon DC, Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR (1997) Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 79: 2237-2242
83. Vogelzang NJ, Herndon II JE, Miller A, Strauss G, Clamon G, Stewart FM, Aisner J, Lyss A, Cooper MR, Suzuki Y, Green MR (1999) High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 10: 597-600
84. Vogelzang NJ, Weissman LB, Herndon II JE, Antman KH, Cooper MR, Corson JM, Green MR (1994) Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol 12: 1436-1442
85. Vorobiof DA, Chasen MR, Abratt R, Rapoport B, Cronje N, Fourie L, McMichael G, Hacking D (2000) Taxotere in malignant pleural mesothelioma. A Phase II clinical trial. Program and abstracts of the 9th World Conference on Lung Cancer; September 11-15, Tokyo, Japan. Abstract 58.
86. White SC, Anderson H, Jayson GC, Ashcroft L, Ranson M, Thatcher N (2000) Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in dvanced non-small-cell lung cancer and mesothelioma. Ann Oncol 11: 201-206
87. Zidar BL, Benjamin RS, Frank J, Lane M, Baker LH (1983) Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study. Am J Clin Oncol 6: 71-74
88. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 6: 223-226
89. Zidar BL, Metch B, Balcerzak SP, Pierce HI, Militello L, Keppen MD, Berenberg JL (1992) A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 70: 2547-2551